News from ambit biosciences corporation A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 13, 2013, 16:02 ET

Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results

 Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology,...

Jul 03, 2013, 14:00 ET

Ambit to Present at JMP Securities Healthcare Conference

Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at...

Jun 26, 2013, 08:00 ET

Data from Phase 2 ACE Study of Ambit's Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) Presented at 18th Congress of the European Hematology Association

Ambit Biosciences Corporation (Nasdaq: AMBI) announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were...

Jun 04, 2013, 08:00 ET

Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology

 Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple presentations from the Phase 2 ACE study of quizartinib (AC220), a...

May 22, 2013, 08:00 ET

Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology

Ambit Biosciences Corporation (Nasdaq: AMBI) today announced that data from clinical investigations of quizartinib (AC220), a potent and selective...

May 16, 2013, 08:00 ET

Ambit Biosciences Announces Pricing of Initial Public Offering

 Ambit Biosciences Corporation today announced the pricing of its initial public offering of 8,125,000 shares of its common stock at $8.00 per...

Apr 15, 2013, 08:00 ET

Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors

 Ambit Biosciences Corporation today announced that David R. Parkinson, M.D., has been appointed to the company's board of directors. Dr....

Mar 11, 2013, 22:00 ET

Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors

 Astellas Pharma Inc. (Astellas) (Tokyo: 4503) and Ambit Biosciences Corporation today announced the companies will end their collaboration for...

Feb 20, 2013, 16:01 ET

Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering

Ambit Biosciences Corporation today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...

Dec 20, 2010, 16:01 ET

Ambit Biosciences Initiates Two Phase I Clinical Trials

Ambit Biosciences (Ambit), today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2)...

Nov 08, 2010, 08:15 ET

Ambit Biosciences Strengthens Board of Directors and Executive Team

Ambit Biosciences Corporation (Ambit) today announced the strengthening of its Board and management team.   "The Board is delighted to...

Nov 05, 2010, 21:25 ET

Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering

Ambit Biosciences Corporation (“Ambit”), announced today that it has filed a registration statement with the Securities and Exchange...

Jul 26, 2010, 08:00 ET

Ambit Biosciences Announces Transition in Company Leadership

Ambit Biosciences Corporation (Ambit), a recognized global leader in kinase drug discovery and development, announced today that its Board of...

Dec 18, 2009, 01:30 ET

Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications

Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and...

Dec 11, 2009, 08:00 ET

Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first...

Dec 07, 2009, 17:30 ET

Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference

Ambit Biosciences Corporation announced today that preliminary results from a clinical trial of its lead product candidate, AC220, in acute...

Dec 07, 2009, 08:30 ET

Ambit Biosciences Corporation Announces Two Poster Presentations Characterizing The Effects of AC220 in Preclinical Models of Acute Myeloid Leukemia at ASH Conference

Ambit Biosciences Corporation announced today the presentation of two posters presenting the results of preclinical studies evaluating AC220 at...

Nov 24, 2009, 11:30 ET

Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3...

Apr 02, 2002, 00:00 ET

Ambit Biosciences and AstraZeneca Enter Proteomics Based Research Collaboration

SAN DIEGO, April 2 /PRNewswire/ -- Ambit Biosciences Corporation, a privately held drug discovery and development company, today announced a...

Nov 07, 2001, 00:00 ET

Ambit Biosciences Completes $10 Million Series B Financing

SAN DIEGO, Nov. 7 /PRNewswire/ -- Ambit Biosciences Corporation, a privately held drug discovery and development company, today announced the...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge